This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Earl A. Palmer, MD; John T. Flynn, MD; Robert J. Hardy, PhD; Dale L. Phelps, MD; Graham E. Quinn, MD; David B. Schaffer, MD
Portland, Ore

Arch Ophthalmol. 1990;108(10):1375-1376.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—The misconception that our report is contradictory deserves a reply, and we welcome the opportunity to further discuss and clarify the intent, design, results, and recommendations of the Multicenter Trial of Cryotherapy for Retinopathy of Prematurity (CRYO-ROP).

This study was designed to test the results of cryotherapy for a defined threshold severity of ROP occurring posterior to zone 3 of the retina. It would have been presumptuous to test for the optimal stage (or other variables) at which to apply a treatment for which efficacy had not previously been adequately studied.

The subgroup of zone 1 cases, when separately analyzed, contains an insufficient sample size to demonstrate a significant benefit in that particular subgroup, even if it exists. However, as our report stated, cryotherapy clearly benefits threshold stage 3+ ROP in zone 2, and the data are consistent with the finding that it also benefits some cases of . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?